Futures fell after Trump said the U.S. will raise tariffs on more than $500 billion worth of Chinese imports, increasing trade tensions.Marketsread more
Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
Hours after President Trump said Sunday he had "second thoughts" about escalating the trade war with China, the White House sought to explain his remark because it was...Politicsread more
President Donald Trump said that he would have a major trade deal with U.K. after it leaves the European Union.Politicsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Despite Kudlow's expectations, China said on Saturday that it strongly opposes Trump's decision to levy additional tariffs on $550 billion worth of Chinese goods, and warned...Politicsread more
President Donald Trump said Sunday he was not happy after North Korea launched short-range ballistic missiles over the weekend.Politicsread more
Bryn Mawr Trust CIO Jeffrey Mills lists where to put money to work as Wall Street copes with trade war and recession jitters.Futures Nowread more
The announcement for Target also comes on the heels of a strong quarterly earnings report, where it showed it drove more people to stores and got them to spend more money...Retailread more
The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Amazon is shaking the medical industry — and now Wall Street's digging up clues on exactly what it has planned.
Jefferies analyst Brian Tanquilut wrote on Friday that he suspects Amazon is growing its professional medical device business, while Wells Fargo pointed out Thursday that Amazon now owns the AmazonRX.com domain.
It's all part of the tea-leaf reading as investors try to understand how Amazon could disrupt a huge and historically difficult-to-break-into industry.
CNBC reported in May that each year, Amazon holds an annual meeting to discuss whether it should break into the pharmacy market, and this year, it's been more serious than ever.
Now, sources have said that is in talks to buy — a deal that would be an unprecedented mega-merger between a top drugstore chain and insurer. RBC Capital Markets analyst George Hill told CNBC that the companies "needed to defend the business from encroachment by Amazon. "
The news roiled , while .
According to Tanquilut, Amazon's business-to-business medical device web page was posted during the same period the company was granted wholesale distribution licenses in several states. The licensure was first reported by the St. Louis Post-Dispatch.
An Amazon spokesperson previously told CNBC by email that the company doesn't "comment on rumors or speculation."
While many have speculated these licenses could be used for drugs, Tanquilut said the timing could indicate Amazon is more interested in medical devices.
"[T]he out-of-state wholesaler license that AMZN filed with the state of Nevada revealed that AMZN did not select 'Controlled Substances' as a type of product that they would be handling," Tanquilut wrote in a Friday research note."While we acknowledge that there are prescription drugs that don't fall under the definition of 'controlled substances', the active decision to choose not to distribute those types of drugs leads us to believe that AMZN will not be using these licenses to distribute any prescription drugs[.]"
On the other hand, Wells Fargo analyst David Maris pointed out that AmazonRX.com redirects to the Amazon home page.
"We find it easy to envision that, if it entered pharmacy, Amazon could offer unique value to some customers, such as the easier ability to manage prescriptions and perhaps discounts, such as free generics to Prime users," Maris wrote. Overall, we think that even though Amazon has not stated a goal to be in pharmacy, history has shown it is better to consider Amazon's disruptive potential beforehand rather than afterward."
— CNBC's Christina Farr, Dan Mangan, Evelyn Cheng and Thomas Franck contributed to this report.